Ferring Pharmaceuticals and North Zealand University Hospital mark first milestone in innovative IBD collaboration
Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation
Ferring announces Phase 3 data for investigational human recombinant FSH with individualised dosing regimen at the 32nd Annual Meeting of ESHRE®
Ferring Pharmaceuticals announces approval of new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label in MRP countries in Europe
Ferring International Center S.A.Ch. de la Vergognausaz 50CH-1162 Saint-PrexSwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 00 10
Email for media enquiries only.For other queries, please see our Contact page.
Ferring International Center S.A.Ch. de la Vergognausaz 50 1162 Saint-PrexSwitzerland
Tel: +41 58 301 00 00Fax: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2016 Ferring B.V.